News >

How to Involve Community Oncologists in Molecular-Based Research-and Expedite Results

Maurie Markman, MD
Published: Friday, Mar 13, 2015

And, assuming the results were again “negative” (regarding objective responses), these definitive data would have been available for viewing by the academic community and prospective patients (following confirmation of the protocol-defined endpoint of futility) within a very short period of time, possibly even 6 months from trial activation.

If this study had been undertaken through the hypothetical process described above, the actual 5-year timeline to report an important negative result could have been reduced to 6 months, or less. Of course, the reporting of positive study results could be similarly expedited.

Finally, the number of such innovative clinical trials that could be ongoing on a national level at the same time theoretically could increase substantially, rather dramatically accelerating research productivity for the benefit of patients everywhere.

Maurie Markman, MD, editor-in-chief, is president of Medicine & Science at Cancer Treatment Centers of America, and clinical professor of Medicine at Drexel University College of Medicine.

Pusztai L, Moulder S, Altan M, et al. Gene signature-guided dasatinib therapy in metastatic breast cancer [published online August 29, 2014]. Clin Cancer Res. 2014;20(20):5265-5271.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication